Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -1.85 | N/A | N/A | N/A |
2024-08-01 | 2024-06 | -3.47 | -3.33 | 0.14 | 4.03% |
2024-05-02 | 2024-03 | -3.59 | -3.07 | 0.52 | 14.48% |
2024-05-02 | 2024-03 | -3.59 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | -0.78 | 0.55 | 1.33 | 170.51% |
2024-02-22 | 2023-12 | -0.78 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Argus Research | Upgrade | Buy | Buy |
2023-08-03 | TD Cowen | Downgrade | Outperform | Market Perform |
2023-08-03 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-03 | B of A Securities | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-08-02 | Deutsche Bank | Downgrade | Buy | Hold |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-07-30 | AFEYAN NOUBAR BOGHOS | Director | 6.86M | Sale |
2022-12-27 | ANDRES JUAN | Chief Technology Officer | 12.80K | Sale |
2024-02-15 | BANCEL STEPHANE J | Chief Executive Officer | 21.08M | Sale |
2024-05-02 | BERENSON STEPHEN A. | Director | 22.20K | Conversion of Exercise of derivative security |
2023-12-05 | GARAY ARPA | Officer | 3.69K | Sale |
2024-09-02 | HOGE STEPHEN | President | 1.60M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 45.71M | 5.55B | 12.01% |
2023-06-29 | Vanguard Group Inc | 27.46M | 3.34B | 7.22% |
2023-06-29 | Blackrock Inc. | 24.16M | 2.94B | 6.35% |
2023-06-29 | State Street Corporation | 14.23M | 1.73B | 3.74% |
2023-06-29 | Flagship Pioneering Inc. | 12.89M | 1.57B | 3.39% |
2023-06-29 | Coatue Management LLC | 6.55M | 795.35M | 1.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.11M | 1.23B | 2.66% |
2023-05-30 | Vanguard International Growth Fund | 9.42M | 1.20B | 2.47% |
2023-06-29 | Vanguard 500 Index Fund | 7.81M | 948.38M | 2.05% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 6.46M | 730.48M | 1.70% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.45M | 523.90M | 1.17% |
2023-05-30 | Fidelity 500 Index Fund | 3.70M | 472.16M | 0.97% |
Split | Date |
---|---|
1 : 10 | 2017-08-03 |
-
Good news coming out soon...
-
Everyone pay close attention to: Lonza.
It’s MRNA , assembly line..
You think someone knows something..
You would be correct. -
Folks, please take a look at Lonza, they’ve been creeping up! That’s a huge sign for MRNA!
-
Huge money flowing in !!
-
When phase three pops this will scream through 80!
-
Phase three still starting this month!
-
No Joke: Tesla Could Be Helping Make a Coronavirus Vaccine
Contributor
Jul 5, 2020 9:04AM EDT
Elon Musk is full of surprises.Some eyebrows were raised earlier this year when the Tesla (NASDAQ: TSLA) CEO proclaimed that his company would make ventilators for COVID-19 patients. But now Tesla appears to be moving into an even more intriguing arena that could impact the fight against the novel coronavirus.
Last week, Musk engaged in a conversation on Twitter about COVID-19 testing. When asked about about his thoughts on RNA vaccines as an approach for immunizing against the novel coronavirus, he replied that he thinks "synthetic RNA (and DNA) has amazing potential." Musk then tweeted, "Tesla, as a side project, is building RNA microfactories for CureVac & possibly others."
Could Tesla really be helping to make RNA vaccines, possibly even one for COVID-19? It doesn't appear that Musk was joking.
-
Could Moderna shares make you a millionaire?
In the near term, everything will depend on the results of the COVID-19 vaccine's clinical trials. As we've seen, the shares are sensitive to good and bad news on the subject.So far, I'm encouraged by trial data. But considering the strong link between this development program and Moderna's share price, I'll wait to see more data on neutralizing antibodies and the vaccine's results in older trial participants -- and whether AstraZeneca takes a clear lead or falls behind -- before I'll call Moderna a millionaire-maker.
-
In response to the report, Moderna CEO Stephane Bancel told CNBC's Meg Tirrell, "we have always said July. And I confirm July." Going to start as soon as possible..
phase 3 this month ! -
$MRNA This stock is dumb as fuck. Avoid like the plague.
-
Big money is jumping in!
-
Everyone notice how Lonza Group stock has been steadily creeping up?
Very good sign! -
Just pick up some more. Buy the dip. Everyone put their big boy pants on...
-
Okay Folks, a complete sissy panic. MRNA, still starting phase three this month just a delay of a few days.. This is a very common occurrence in this industry.
-
Buy the dip!
-
Going down down !!
-
Wait for the big
-
The only phase 3 on the planet!
-
Today has been a serious buying opportunity!
-
Folks, this a fantastic buying opportunity!!
-
NTx Services Launches to Supercharge Next Generation mRNA Research
businesswire.com • -
Moderna (NASDAQ:MRNA) Shares Up 7%
news.google.com • -
Moderna (NASDAQ:MRNA) PT Lowered to $48.00
news.google.com • -
What's Going On With Moderna Shares Tuesday?
news.google.com • -
Where are the Opportunities in (MRNA)
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein
news.google.com • -
Moderna's Recent Drop: 4 Reasons Bulls See Opportunity
marketbeat.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Class Action Lawsuit Against Moderna, Inc. (NASDAQ:MRNA)
news.google.com • -
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
news.google.com • -
Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut
news.google.com • -
‘Time to Move to the Sidelines,’ Says Jefferies About Moderna Stock
news.google.com • -
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
news.google.com • -
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts
news.google.com • -
Moderna's Move Shows Lack Of Confidence, Shrinks Pipeline (NASDAQ:MRNA)
news.google.com • -
Moderna: Looking For The Bottom (NASDAQ:MRNA)
news.google.com • -
Moderna stock slides on downgrades tied to profitability delay
news.google.com • -
Moderna Stock Falls Again. How the Drug Maker Can Turn Things Around.
news.google.com • -
Moderna: Oddo BHF reduces its target after CMD
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Big Rate Cut or Small, U.S. Stocks Are Priced for Middling Returns
news.google.com • -
Moderna Stock Hits Lowest Since 2020. What’s Behind the Tumble.
news.google.com • -
Biggest stock movers today: MPW, MRNA, NTGR, and more
news.google.com • -
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
news.google.com • -
Moderna Stock Plummets on Cost-Cutting Measures
news.google.com • -
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
news.google.com • -
Biggest stock movers today: WBD, MPW, MRNA, SIG, and more
news.google.com • -
Moderna stock plunges after slashing R&D budget
news.google.com • -
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
news.google.com •